The effectiveness of riboflavin and ultraviolet light pathogen reduction technology in eliminating Trypanosoma cruzi from leukoreduced whole blood

Transfusion

Volumn 57, Issue 6, 2017, Pages 1440-1447

  Jimenez Marco, Teresa ^a,b   Cancino Faure, Beatriz ^c   Girona Llobera, Enrique ^a,b   Alcover, M Magdalena ^c   Riera, Cristina ^c   Fisa, Roser ^c  

^a Fundació Banc de Sang i Teixits de las Illes Balears   (Spain)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RIBOFLAVIN; RNA;

ARTICLE; BLOOD FILTRATION; BLOOD TRANSFUSION; CHAGAS DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; HUMAN; NONHUMAN; NORMAL HUMAN; PARASITE CLEARANCE; PARASITE TRANSMISSION; PARASITE VIABILITY; PATHOGEN REDUCTION SYSTEM; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET RADIATION; BLOOD STORAGE; DRUG EFFECTS; LEUKAPHERESIS; PATHOGENICITY; PROCEDURES; RADIATION RESPONSE; TRYPANOSOMA CRUZI;

BLOOD PRESERVATION; CHAGAS DISEASE; LEUKOCYTE REDUCTION PROCEDURES; RIBOFLAVIN; TRYPANOSOMA CRUZI; ULTRAVIOLET RAYS;

EID: 85017565086     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14071     Document Type: Article

References (38)

1. Pan American Health Organization. World Health Organization. Regional Office for the Americas. Chagas disease [Internet]. Available from: http://www.paho.org/hq/index.php.
2. Bern C. Chagas' disease. N Engl J Med 2015;373:456-66.
3. Benjamin RJ, Stramer SL, Leiby DA, et al. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission (CME). Transfusion 2012;52:1913-21.
4. Centers for Disease Control and Prevention. Chagas disease after organ transplantation—Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006;55:798-800.
5. Soriano-Arandes A, Angheben A, Serre-Delcor N, et al. Control and management of congenital Chagas disease in Europe and other non-endemic countries: current policies and practices. Trop Med Int Health 2016;21:590-6.
6. Duffy T, Bisio M, Altcheh J, et al. Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in Chagas disease patients. PLoS Negl Trop Dis 2009;3:e419.
7. Cancino-Faure B, Fisa R, Riera C, et al. Evidence of meaningful levels of Trypanosoma cruzi in platelet concentrates from seropositive blood donors. Transfusion 2015;55:1249-55.
8. Weinman D, MacAlister J. Prolonged storage of human pathogenic protozoa with conservation of virulence; observations on the storage of helminths and leptospiras. Am J Hyg 1947;45:102-21.
9. Filardi LS. Cryopreservation of Trypanosoma cruzi bloodstream forms. J Protozool 1975;22:398-401.
10. Cardo LJ, Salata J, Mendez J, et al. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light. Transfus Apher Sci 2007;37:131-7.
11. Tonnetti L, Thorp AM, Reddy HL, et al. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood. Transfusion 2012;52:409-16.
12. Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013;53:131S-136S.
13. Piron M, Fisa R, Casamitjana N, et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Tropica 2007;103:195-200.
14. Souto R, Zingales B. Sensitive detection and strain classification of Trypanosoma cruzi by amplification of a ribosomal RNA sequence. Mol Biochem Parasitol 1993;62:45-52.
15. Conners EE, Vinetz JM, Weeks JR, et al. A global systematic review of Chagas disease prevalence among migrants. Acta Trop 2016;156:68-78.
16. Agapova M, Busch MP, Custer B. Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi. Transfusion 2010;50:2220-32.
17. Wilkinson SL, Lipton KS. Leukocyte reduction. Association Bulletin #99-7. Bethesda (MD): AABB; 1999.
18. European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Guide to the preparation, use and quality assurance of blood components. 18th ed. Strasbourg: European Directorate for the Quality of Medicines & Health Care (EDQM); 2015.
19. Gilliss BM, Looney MR, Gropper MA. Reducing non-infectious risks of blood transfusion. Anesthesiology 2011;115:635-49.
20. La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol 1997;35:2715-27.
21. Mettille FC, Salata KF, Belanger KJ, et al. Reducing the risk of transfusion-transmitted rickettsial disease by WBC filtration, using Orientia tsutsugamushi in a model system. Transfusion 2000;40:290-6.
22. Kyriakou D, Alexandrakis M, Passam F, et al. Quick detection of Leishmania in peripheral blood by flow cytometry. Is prestorage leucodepletion necessary for leishmaniasis prevention in endemic areas? Transfus Med 2003;13:59-62.
23. Riera C, Fisa R, López-Chejade P, et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008;48:1383-9.
24. Cardo LJ, Salata J, Harman R, et al. Leukodepletion filters reduce Leishmania in blood products when used at collection or at the bedside. Transfusion 2006;46:896-902.
25. Cardo LJ, Asher L. Electron micrographic study of the removal of Trypanosoma cruzi from blood products by leukodepletion filters. Transfusion 2006;46:1067-8.
26. Cardo LJ, Salata J, Wilder D. Removal of Plasmodium falciparum-infected red blood cells from whole blood by leukoreduction filters. Transfusion 2009;49:337-46.
27. Moraes-Souza H, Bordin JO, Bardossy L, et al. Prevention of transfusion-associated Chagas' disease: efficacy of white cell reduction filters in removing Trypanosoma cruzi from infected blood. Transfusion 1995;35:723-6.
28. Mundt JM, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957-64.
29. Tonnetti L, Thorp AM, Reddy HL, et al. Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood. Transfusion 2013;53:860-7.
30. Owusu-Ofori S, Kusi J, Owusu-Ofori A, et al. Treatment of whole blood with riboflavin and UV light: impact on malaria parasite viability and whole blood storage. Shock 2015;44 Suppl 1:33-8.
31. Tonnetti L, Thorp AM, Reddy HL, et al. Reduction of Leishmania donovani infectivity in whole blood using riboflavin and ultraviolet light. Transfusion 2015;55:326-9.
32. Chiari E, Dias JC, Lana M, et al. Hemocultures for the parasitological diagnosis of human chronic Chagas' disease. Rev Soc Bras Med Trop 1989;22:19-23.
33. Luz ZM. Changes in the hemoculture methodology improve the test positivity. Mem Inst Oswaldo Cruz 1999;94:295-8.
34. El Chaar M, Atwal S, Freimanis GL, et al. Inactivation of Plasmodium falciparum in whole blood by riboflavin plus irradiation. Transfusion 2013;53:3174-83.
35. Marschner S, Fast LD, Baldwin WM III, et al. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010;50:2489-98.
36. Adams ER, Schoone GJ, Ageed AF, et al. Development of a reverse transcriptase loop-mediated isothermal amplification (LAMP) assay for the sensitive detection of Leishmania parasites in clinical samples. Am J Trop Med Hyg 2010;82:591-6.
37. Baque RH, Gilliam AO, Robles LD, et al. A real-time RT-PCR method to detect viable Giardia lamblia cysts in environmental waters. Water Res 2011;45:3175-84.
38. Vallejo AF, García J, Amado-Garavito AB, et al. Plasmodium vivax gametocyte infectivity in sub-microscopic infections. Malar J 2016;15:48.